Direct-to-Patient Market Report 2022-2032

The Direct-to-Patient Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Industry Focus on Patient-Centricity Is Driving the Market Growth

The direct-to-patient and home trial support (DtP/HTS) strategy can provide priceless assistance to patients, regardless of whether they are getting a commercial therapy that has been approved or are taking part in a clinical trial. The DtP strategy has developed over the past ten years, with global adoption expanding dramatically in the last three years, fuelled by an industry focus on patient-centricity that is becoming more intense. This strategy provides considerable benefits for the patient as well as all other parties by enabling patients to obtain individualised care, cutting-edge or well-established therapies without leaving the comfort of their own homes. Technology has changed every part of our everyday life, which makes the world feel smaller than it has ever been.

Businesses in the medical, healthcare, and pharmaceutical industries have refrained from embracing social media for a variety of reasons. Corporations welcomed it, but pharmacists baulked because they thought it would present an excessive amount of legal risk. Even so, a few forerunners in the direct-to-patient sector have prepared the way for others. They have demonstrated that, in the quickly evolving healthcare environment of today, it is not only doable but also crucial. Tens of thousands of branding exercises are sent to patients in the medical field each day.

What Questions Should You Ask before Buying a Market Research Report?

How is the direct-to-patient (DTP) market evolving?
What is driving and restraining the direct-to-patient (DTP) market?
How will each direct-to-patient (DTP) submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
How will the market shares for each direct-to-patient (DTP) submarket develop from 2022 to 2032?
What will be the main driver for the overall market from 2022 to 2032?
Will leading direct-to-patient (DTP) markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
Who are the leading players and what are their prospects over the forecast period?
What are the direct-to-patient (DTP) projects for these leading companies?
How will the industry evolve during the period between 2022 and 2032? What are the implications of direct-to-patient (DTP) projects taking place now and over the next 10 years?
Is there a greater need for product commercialisation to further scale the direct-to-patient (DTP) market?
Where is the direct-to-patient (DTP) market heading and how can you ensure you are at the forefront of the market?
What are the best investment options for new product and service lines?
What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the direct-to-patient (DTP) market today, and over the next 10 years:

Our 344-page report provides 155 tables and 165 charts/graphs exclusively to you.
The report highlights key lucrative areas in the industry so you can target them - NOW.
It contains in-depth analysis of global, regional and national sales and growth.
It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the direct-to-patient (DTP) market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects

In addition to revenue forecasting to 2032, the new study provides you with recent results, growth rates, and market shares.
You will find original analyses, with business outlooks and developments.
Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising direct-to-patient (DTP) prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Type

Direct-to-Patient Marketing
Direct-to-Patient Health Services
Direct-to-Patient Clinical Trials
Direct-to-Patient Logistics

Direct-to-Patient Marketing

DTC Prescribed Drug Advertising
Disease Awareness Campaigns
Brand Promotion
Healthcare Services Promotion
Laboratory Testing Promotion
Other Direct-to-Patient Marketing

Direct-to-Patient Health Services

Tele Consultation
Drug Prescription
Medical Call Centers
Telesampling
Online Services

Direct-to-Patient Clinical Trials

Tele Health Screening
Investigational Medicinal Product (IMP)
Patient Support Systems
Other Clinical Trial Services

Direct-to-Patient Logistics

Prescribed Medicine Delivery
Pre-Clinical Supplies
Clinical Trial Supplies
Home Trial Support
Test Samples Collection
Rest All CSO Services

Therapeutics

Cardiovascular Disease
Respiratory Diseases
Oncology
Infectious Diseases
Dermatology
Other Therapeutics

Model

Depot-to-Patient
Site-to-Patient
Hybrid Model
Direct-From-Patient (DfP)
Other DtP Models

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America

U.S.
Canada

Europe

Germany
UK
France
Italy
Spain
Rest of Europe

Asia Pacific

China
Japan
India
Australia
South Korea
Rest of Asia Pacific

MEA

Turkey
Saudi Arabia
South Africa
UAE
Rest of MEA

Latin America

Brazil
Mexico
Rest of Latin America

The report also includes profiles and for some of the leading companies in the Direct-to-Patient Market Report 2022-2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth

Access TeleCare
Agnity Inc.
AMD Global Telemedicine
American Well
Avel eCare
Axs Health
Babylon Health
Citius Tech
Dictum Health Inc.
Doctor Anywhere
Doctor on Demand
Health Partners
Health Tap
HIMS
Marken
20/20 NOW
NURX
Practo Technologies Pvt. Ltd.
Specialists on call, Inc.
Teladoc Health Inc.
True pill
Up Script Health

Overall world revenue for Direct-to-Patient (DTP) Market, 2022 to 2032 in terms of value the market will surpass US$40,746 million in 2022, this work calculates. We predict strong revenue growth through to 2032. this work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Direct-to-Patient Market Report 2022-2032 report help you?

In summary, this 340+ page report provides you with the following knowledge:

Revenue forecasts to 2032 for Direct-to-Patient (DTP) Market, 2022 to 2032 Market, with forecasts for type, direct-to-patient marketing, direct-to-patient health services, clinical trials, direct-to-patient logistics, therapeutics, and model, each forecast at a global and regional level - discover the industry’s prospects, finding the most lucrative places for investments and revenues.
Revenue forecasts to 2032 for five regional and 20 key national markets - See forecasts for the Direct-to-Patient (DTP) Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and LAMEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.
Prospects for established firms and those seeking to enter the market - including company profiles for 22 of the major companies involved in the Direct-to-Patient (DTP) Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only this report contains, staying informed with invaluable business intelligence.

Information found nowhere else

With this new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how this work could benefit your research, analyses, and decisions. The study is for everybody needing commercial analyses for the Direct-to-Patient (DTP) Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

1 Report Overview

1.1 Objectives of the Study
1.2 Introduction to Direct-To-Patient Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Reports
1.10 About

2 Executive Summary

3 Market Overview

3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Increase in Social Media's Relevance
3.2.1.2 Direct-to-Patient Marketing Driven by Decentralization
3.2.1.3 Recognizing the Value of Direct-to-Patient
3.2.2 Market Restraining Factors
3.2.2.1 Legal restrictions Are Impeding the Expansion of the DTP Market
3.2.2.2 Development of Digital Technology Projected to Boost Industry Growth
3.2.2.3 Booming Telehealth to Fuel Market Growth
3.2.3 Market Opportunities
3.2.3.1 DTP Services Are not Just for Delivering Medications
3.2.3.2 DTP Would be the Primary Point of Contact for Patient Support
3.2.3.3 DTP's Integration into Medical Universities, Clinics, and Hospitals
3.3 Supply Chain
3.4 COVID-19 Impact Analysis
3.4.1 COVID Impact Market Analysis (V-Shaped Recovery Scenario)
3.4.2 COVID Impact Market Analysis (W-Shaped Recovery Scenario)
3.4.3 COVID Impact Market Analysis (U-Shaped Recovery Scenario)
3.4.4 COVID Impact Market Analysis (L-Shaped Recovery Scenario)
3.5 Porter’s Five Forces Analysis
3.5.1 Supplier Power
3.5.2 Buyer Power
3.5.3 Competitive Rivalry
3.5.4 Threat from Substitutes
3.5.5 Threat of New Entrants
3.6 PEST Analysis
3.6.1 Political Factors
3.6.2 Economic Factors
3.6.3 Social Factors
3.6.4 Technological Factors

4 Direct-to-Patient Market Analysis by Type

4.1 Key Findings
4.2 Type Segment: Market Attractiveness Index
4.3 Direct-to-Patient Marketing
4.4 Direct-to-Patient Health Services
4.5 Direct-to-Patient Clinical Trials
4.6 Direct-to-Patient Logistics
4.7 Direct-To-Patient Market by Type

5 Direct-To-Patient Market Analysis by Marketing

5.1 Key Findings
5.2 Marketing Segment: Market Attractiveness Index
5.3 DTC Prescribed Drug Advertising
5.4 Disease Awareness Campaigns
5.5 Brand Promotion
5.6 Healthcare Services Promotion
5.7 Laboratory Testing Promotion
5.8 Other Direct-to-Patient Marketing
5.9 Direct-to-Patient Market by Marketing

6 Direct-to-Patient Market Analysis by Direct-to-Patient Health Services

6.1 Key Findings
6.2 Direct-to-Patient Health Services Segment: Market Attractiveness Index
6.3 Tele Consultation
6.4 Drug Prescription
6.5 Medical Call Centers
6.6 Telesampling
6.7 Online Services
6.8 Direct-to-Patient Market by Health Service

7 Direct-to-Patient Market Analysis by Clinical Trials

7.1 Key Findings
7.2 Clinical Trials Segment: Market Attractiveness Index
7.3 Tele Health Screening
7.4 Investigational Medicinal Product (IMP)
7.5 Patient Support Systems
7.6 Other Clinical Trial Services
7.7 Direct-to-Patient Market by Clinical Trials

8 Direct-to-Patient Market Analysis by Direct-to-Patient Logistics

8.1 Key Findings
8.2 Direct-to-Patient Logistics Segment: Market Attractiveness Index
8.3 Prescribed Medicine Delivery
8.4 Pre-Clinical Supplies
8.5 Clinical Trial Supplies
8.6 Home Trial Support
8.7 Test Samples Collection
8.8 Direct-to-Patient Market by Logistics

9 Direct-to-Patient Market Analysis by Therapeutics

9.1 Key Findings
9.2 Therapeutics Segment: Market Attractiveness Index
9.3 Cardiovascular Diseases
9.4 Respiratory Diseases
9.5 Oncology
9.6 Infectious Diseases
9.7 Dermatology
9.8 Other Therapeutics
9.9 Direct-to-Patient Market by Therapeutics
10 Direct-to-Patient Market Analysis by Model
10.1 Key Findings
10.2 Model Segment: Market Attractiveness Index
10.3 Site-to-Patient
10.4 Hybrid Model
10.5 Direct-From-Patient (DfP)
10.6 Other DtP Models
10.7 Direct-to-Patient Market by Model

11 Direct-to-Patient Market Analysis by Region

11.1 Key Findings
11.2 Direct-to-Patient Market Attractiveness Index by Region
11.3 Direct-to-Patient Market Forecast
11.4 Direct-to-Patient Market by Region

12 North America Direct-To-Patient Market Analysis

12.1 Key Findings
12.2 Growing Desire for In-Home Care
12.3 Multinational DtP Company Presence in the Region
12.4 North America Direct-To-Patient Market Attractiveness Index by Region
12.5 Direct-to-Patient Market by Value
12.6 North America Direct-to-Patient Market by Marketing
12.7 North America Direct-to-Patient Market by Health Services
12.8 North America Direct-to-Patient Market by Clinical Trials
12.9 North America Direct-to-Patient Market by Logistics
12.10 North America Direct-to-Patient Market by Therapeutics
12.11 North America Direct-to-Patient Market by Model
12.12 North America Direct-to-Patient Market by Country
12.13 U.S. Direct-to-Patient Market Analysis
12.13.1 Rising Healthcare Costs Are Anticipated to Accelerate the Uptake of Telehealth
12.13.2 U.S. Laws for DTP Businesses
12.14 Canada Direct-to-Patient Market Analysis
12.14.1 Increasing Preference for Remote and Home Monitoring

13 Europe Direct-To-Patient Market Analysis

13.1 Key Findings
13.2 Significant Investment in Clinical Research Infrastructure
13.3 How DtP Supports Clinical Trial Innovation?
13.4 Europe Direct-to-Patient Market Attractiveness Index by Region
13.5 Europe Direct-to-Patient Market by Value
13.6 Europe Direct-to-Patient Market by Type
13.7 Europe Direct-to-Patient Market by Marketing
13.8 Europe Direct-to-Patient Market by Health Services
13.9 Europe Direct-to-Patient Market by Clinical Trials
13.10 Europe Direct-to-Patient Market by Logistics
13.11 Europe Direct-to-Patient Market by Therapeutics
13.12 Europe Direct-to-Patient Market by Model
13.13 Europe Direct-to-Patient Market by Country
13.14 Germany Direct-To-Patient Market Analysis
13.14.1 Germany's DTP Market Growing Due to Good Health Reimbursement Policies
13.14.2 Numerous Telemedicine Systems Are Now in Use
13.15 U.K. Direct-To-Patient Market Analysis
13.15.1 Hospital-based Care Trend Shifting to Home Care
13.15.2 Ageing Population Will Bring Opportunities for DTP
13.16 France Direct-To-Patient Market Analysis
13.16.1 Significant Fragmentation in the Direct-to-Patient Services Market
13.17 Italy Direct-to-Patient Market Analysis
13.17.1 Quality and Effectiveness of the Italian Healthcare System Can Occasionally Be Criticised
13.17.2 Laws Concerning the Delivery of DTP Services
13.18 Spain Direct-To-Patient Market Analysis
13.18.1 The Healthcare System in Spain is Among the Best in the World
13.19 Rest of Europe Direct-To-Patient Market Analysis

14 Asia-Pacific Direct-To-Patient Market Analysis

14.1 Key Findings
14.2 Growing Health Consumerism
14.3 A Shift in Stakeholder Confidence
14.4 Asia Pacific Direct-to-Patient Market Attractiveness Index by Region
14.5 Asia Pacific Direct-to-Patient Market by Value
14.6 Asia Pacific Direct-to-Patient Market by Type
14.7 Asia Pacific Direct-to-Patient Market by Marketing
14.8 Asia Pacific Direct-to-Patient Market by Health Services
14.9 Asia Pacific Direct-to-Patient Market by Clinical Trials
14.10 Asia Pacific Direct-to-Patient Market by Logistics
14.11 Asia Pacific Direct-to-Patient Market by Therapeutics
14.12 Asia Pacific Direct-to-Patient Market by Model
14.13 Asia Pacific Direct-to-Patient Market by Country
14.14 China Direct-to-Patient Market Analysis
14.14.1 Government Made "Direct-To-Patients" Shipment of Investigational Drugs Mandatory
14.15 India Direct-to-Patient Market Analysis
14.15.1 Country's Healthcare System is Transitioning to the DtP Model
14.15.2 Telemedicine in India
14.16 Japan Direct-to-Patient Market Analysis
14.16.1 DtP Services Are Becoming More Popular in Japan
14.16.2 Close Patient Engagement is a Majorly Emerging Sector for Japanese Pharma
14.17 Australia Direct-to-Patient Market Analysis
14.17.1 Australian Government Offers Packages for Home Care Package (HCP)
14.17.2 Remarkable Growth of Australia's Market for Direct-To-Patient
14.18 South Korea Direct-to-Patient Market Analysis
14.19 Rest of Asia-Pacific Direct-to-Patient Market Analysis

15 Latin America Direct-To-Patient Market Analysis

15.1 Key Findings
15.2 Latin America Direct-to-Patient Market Attractiveness Index by Region
15.3 Latin America Direct-To-Patient Market by Value
15.4 Latin America Direct-To-Patient Market by Type
15.5 Latin America Direct-To-Patient Market by Marketing
15.6 Latin America Direct-To-Patient Market by Health Services
15.7 Latin America Direct-To-Patient Market by Clinical Trials
15.8 Latin America Direct-To-Patient Market by Logistics
15.9 Latin America Direct-To-Patient Market by Therapeutics
15.10 Latin America Direct-To-Patient Market by Model
15.11 Latin America Direct-To-Patient Market by Country
15.12 Brazil Direct-to-Patient Market Analysis
15.12.1 Government Policies for the DTP Industry
15.13 Mexico Direct-to-Patient Market Analysis
15.14 Rest of Latin America Direct-to-Patient Market Analysis

16 MEA Direct-To-Patient Market Analysis

16.1 Key Findings
16.2 MEA Direct-to-Patient Market Attractiveness Index by Region
16.3 MEA Direct-To-Patient Market by Value
16.4 MEA Direct-To-Patient Market by Type
16.5 MEA Direct-To-Patient Market by Marketing
16.6 MEA Direct-To-Patient Market by Health Services
16.7 MEA Direct-To-Patient Market by Clinical Trials
16.8 MEA Direct-To-Patient Market by Logistics
16.9 MEA Direct-To-Patient Market by Therapeutics
16.10 MEA Direct-To-Patient Market by Model
16.11 MEA Direct-To-Patient Market by Country
16.12 Saudi Arabia Direct-to-Patient Market Analysis
16.12.1 Saudi Arabia Government is Developing and Improving Healthcare Services Through a Transformation Plan
16.13 Turkey Direct-to-Patient Market Analysis
16.13.1 Direct To Patient Has a Large Distribution Network that Reaches All Regions of Turkey
16.13.2 Turkey’s Family Medicine Reform Will Boost Demand for DtP Services in Nearing Future
16.14 UAE Direct-to-Patient Market Analysis
16.14.1 Rise in Healthcare Demand in the United Arab Emirates
16.14.2 UAE is Moving Toward DtP and Telehealth Models
16.15 South Africa Direct-to-Patient Market Analysis
16.15.1 Professional Training is Required for DtP Service Providers
16.15.2 Patient's Cultural and Family Context at Home Must Include Professional DTP
16.16 Rest of MEA Direct-to-Patient Market Analysis
16.16.1 Start-Ups in the Nation Could Destabilise the DTP Market

17 Competitive Landscape

17.1 Key Business Strategy Analysis- Agreement
17.2 Key Business Strategy Analysis- Contract
17.3 Key Business Strategy Analysis- Expansion
17.4 Key Business Strategy Analysis- Partnership
17.5 Key Business Strategy Analysis- Launch

18 Company Profiles

18.1 Access TeleCare
18.1.1 Company Snapshot
18.1.2 Company Overview
18.1.3 Product Benchmarking
18.1.4 Strategic Outlook
18.2 Agnity Inc.
18.2.1 Company Snapshot
18.2.2 Company Overview
18.2.3 Product Benchmarking
18.2.4 Strategic Outlook
18.3 AMD Global Telemedicine
18.3.1 Company Snapshot
18.3.2 Company Overview
18.3.3 Product Benchmarking
18.3.4 Strategic Outlook
18.4 American Well
18.4.1 Company Snapshot
18.4.2 Company Overview
18.4.3 Financial Analysis
18.4.3.1 Net Revenue, 2018-2021
18.4.3.2 Operating Income, 2018-2021
18.4.3.3 Research & Development Expenses, 2018-2021
18.4.4 Product Benchmarking
18.4.5 Strategic Outlook
18.5 Avel eCare
18.5.1 Company Snapshot
18.5.2 Company Overview
18.5.3 Product Benchmarking
18.5.4 Strategic Outlook
18.6 Axs Health
18.6.1 Company Snapshot
18.6.2 Company Overview
18.6.3 Product Benchmarking
18.6.4 Strategic Outlook
18.7 Babylon Health
18.7.1 Company Snapshot
18.7.2 Company Overview
18.7.2.1 Net Revenue, 2019-2021
18.7.2.2 Operating Income, 2019-2021
18.7.2.3 R&D Expenses, 2019-2021
18.7.3 Product Benchmarking
18.7.4 Strategic Outlook
18.8 Citius Tech
18.8.1 Company Snapshot
18.8.2 Company Overview
18.8.3 Product Benchmarking
18.8.4 Strategic Outlook
18.9 Dictum Health Inc.
18.9.1 Company Snapshot
18.9.2 Company Overview
18.9.3 Product Benchmarking
18.9.4 Strategic Outlook
18.10 Doctor Anywhere
18.10.1 Company Snapshot
18.10.2 Company Overview
18.10.3 Product Benchmarking
18.10.4 Strategic Outlook
18.11 Doctor on Demand
18.11.1 Company Snapshot
18.11.2 Company Overview
18.11.3 Product Benchmarking
18.11.4 Strategic Outlook
18.12 Health Partners
18.12.1 Company Snapshot
18.12.2 Company Overview
18.12.3 Financial Analysis
18.12.3.1 Net Revenue, 2018-2020
18.12.3.2 Operating Income, 2018-2020
18.12.4 Product Benchmarking
18.12.5 Strategic Outlook
18.13 Health Tap
18.13.1 Company Snapshot
18.13.2 Company Overview
18.13.3 Product Benchmarking
18.13.4 Strategic Outlook
18.14 HIMS
18.14.1 Company Snapshot
18.14.2 Company Overview
18.14.3 Financial Analysis
18.14.3.1 Net Revenue, 2019-2021
18.14.3.2 Operating Income, 2019-2021
18.14.4 Product Benchmarking
18.14.5 Strategic Outlook
18.15 Marken
18.15.1 Company Snapshot
18.15.2 Company Overview
18.15.3 Product Benchmarking
18.15.4 Strategic Outlook
18.16 20/20 NOW
18.16.1 Company Snapshot
18.16.2 Company Overview
18.16.3 Product Benchmarking
18.16.4 Strategic Outlook
18.17 NURX
18.17.1 Company Snapshot
18.17.2 Company Overview
18.17.3 Product Benchmarking
18.17.4 Strategic Outlook
18.18 Practo Technologies Pvt. Ltd
18.18.1 Company Snapshot
18.18.2 Company Overview
18.18.3 Product Benchmarking
18.18.4 Strategic Outlook
18.19 Specialists on call, Inc
18.19.1 Company Snapshot
18.19.2 Company Overview
18.19.3 Financial Analysis
18.19.3.1 Net Revenue, 2019-2021
18.19.3.2 Research & Development Expense, 2019-2021
18.19.4 Product Benchmarking
18.19.5 Strategic Outlook
18.20 Teladoc Health Inc
18.20.1 Company Snapshot
18.20.2 Company Overview
18.20.3 Financial Analysis
18.20.3.1 Net Revenue, 2017-2021
18.20.3.2 Operating Income, 2017-2021
18.20.3.3 Research & Development Expenses, 2017-2021
18.20.4 Product Benchmarking
18.20.5 Strategic Outlook
18.21 True pill
18.21.1 Company Snapshot
18.21.2 Company Overview
18.21.3 Product Benchmarking
18.21.4 Strategic Outlook
18.22 Up Script Health
18.22.1 Company Snapshot
18.22.2 Company Overview
18.22.3 Product Benchmarking
18.22.4 Strategic Outlook

19 Conclusion and Recommendations

19.1 Concluding Remarks from
19.2 Recommendations for Market Players

Companies Mentioned

Access TeleCare
Agnity Inc.
AMD Global Telemedicine
American Well
Avel eCare
Axs Health
Babylon Health
Citius Tech
Dictum Health Inc.
Doctor Anywhere
Doctor on Demand
Health Partners
Health Tap
HIMS
Marken
20/20 NOW
NURX
Practo Technologies Pvt. Ltd.
Specialists on call, Inc.
Teladoc Health Inc.
True pill
Up Script Health
Antidote
Athenahealth, Inc.
AutoCruitment
BBK Worldwide
Cerner Corporation
Clariness
ClinicalConnection
CSSi
Curavit
Elligo Health Research
Getwell Network, Inc.
IBM
Lincor Solutions
McKesson Corporation
Medecision, Inc.
MMG
Orion Health Ltd.
Phytel Inc.
Praxis
Science37
StudyKik
TrialSpark
TrialX
Welvu
Yourcareuniverse, Inc.
Africa Centres for Disease Control and Prevention (Africa CDC)
American Association of Medical Colleges (AAMC)
Astar's Genome institute of Singapore (GIS)
Biotechnology Industry Research Assistance council (BIRAC)
Clinical Laboratory Improvement Amendments (CLIA)
Clinical Laboratory Improvement Amendments (CLIA)
Diagnostic Related Group (DRG)
Food and Drug Administration (FDA)
Indian Department of Biotechnology (DBT)
Indian institute of technology (IIT)
Indian Medical Device Industry (AIMED)
International Diabetes Federation (IDF)
International Organisation for Standardisation (ISO)
The Foundation for Innovative New Diagnostics (FIND)
World health Organization (WHO)

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4917EUR$5,123USD£3,950GBP
1 - 5 USER LICENSE PDF	The product is a PDF.	This is a 1-5 user license, allowing up to five users have access to the product.	€5602EUR$5,836USD£4,500GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6846EUR$7,133USD£5,500GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€8651EUR$9,013USD£6,950GBP